Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Br, Bettencourt"'
Autor:
Misra S, Ma, Crosby, Christopher Mungall, Bb, Matthews, Ks, Campbell, Hradecky P, Huang Y, Js, Kaminker, Gh, Millburn, Se, Prochnik, Cd, Smith, Jl, Tupy, Ej, Whitfied, Bayraktaroglu L, Bp, Berman, Br, Bettencourt, Se, Celniker, Ad, Grey, Ra, Drysdale, Nl, Harris, Richter J, Russo S, Aj, Schroeder, Sq, Shu, Stapleton M, Yamada C, Ashburner M, Wm, Gelbart, Gm, Rubin, Se, Lewis
Publikováno v:
Scopus-Elsevier
Genome Biology
Europe PubMed Central
Genome Biology
Europe PubMed Central
The recent completion of the Drosophila melanogaster genomic sequence to high quality, and the availability of a greatly expanded set of Drosophila cDNA sequences, afforded FlyBase the opportunity to significantly improve genomic annotations.
Ba
Ba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c6fc9768d10fed6c4022757f6467813e
http://www.scopus.com/inward/record.url?eid=2-s2.0-0002636459&partnerID=MN8TOARS
http://www.scopus.com/inward/record.url?eid=2-s2.0-0002636459&partnerID=MN8TOARS
Autor:
Dunaj SJ; Department of Biological Sciences, University of Massachusetts Lowell, Lowell, MA, USA., Bettencourt BR; Triplet Therapeutics, Cambridge, MA, USA., Garb JE; Department of Biological Sciences, University of Massachusetts Lowell, Lowell, MA, USA., Brucker RM; The Rowland Institute of Harvard University, Cambridge, MA, USA. brucker@rowland.harvard.edu.
Publikováno v:
BMC evolutionary biology [BMC Evol Biol] 2020 Aug 18; Vol. 20 (1), pp. 104. Date of Electronic Publication: 2020 Aug 18.
Autor:
Liebow A; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and aliebow@alnylam.com., Li X; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama., Racie T; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and., Hettinger J; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and., Bettencourt BR; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and., Najafian N; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and., Haslett P; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and., Fitzgerald K; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and., Holmes RP; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama., Erbe D; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and., Querbes W; Alnylam Pharmaceuticals, Departments of Research and Development, Cambridge, Massachusetts; and., Knight J; Department of Urology, University of Alabama at Birmingham, Birmingham, Alabama.
Publikováno v:
Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2017 Feb; Vol. 28 (2), pp. 494-503. Date of Electronic Publication: 2016 Jul 18.
Autor:
Fitzgerald K; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., White S; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Borodovsky A; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Bettencourt BR; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Strahs A; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Clausen V; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Wijngaard P; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Horton JD; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Taubel J; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Brooks A; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Fernando C; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Kauffman RS; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Kallend D; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Vaishnaw A; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.)., Simon A; From Alnylam Pharmaceuticals, Cambridge, MA (K.F., S.W., A. Borodovsky, B.R.B., A. Strahs, V.C., R.S.K., A.V., A. Simon); the Medicines Company, Parsippany, NJ (P.W., D.K.); University of Texas Southwestern Medical Center, Dallas (J.D.H.); Richmond Pharmacology, St. George's University of London, London (J.T.); and Covance Clinical Research Unit, Leeds, United Kingdom (A. Brooks, C.F.).
Publikováno v:
The New England journal of medicine [N Engl J Med] 2017 Jan 05; Vol. 376 (1), pp. 41-51. Date of Electronic Publication: 2016 Nov 13.
Autor:
Zimmermann TS; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA. Electronic address: tzimmermann@alnylam.com., Karsten V; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Chan A; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Chiesa J; Covance Clinical Research Unit Ltd., Leeds LS2 9LH, UK., Boyce M; Hammersmith Medicines Research Ltd., London NW10 7EW, UK., Bettencourt BR; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Hutabarat R; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Nochur S; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Vaishnaw A; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA., Gollob J; Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2017 Jan 04; Vol. 25 (1), pp. 71-78. Date of Electronic Publication: 2017 Jan 04.
Autor:
Butler JS; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Chan A; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Costelha S; b Instituto de Investigação e Inovação em Saúde, Universidade do Porto , Porto , Portugal .; c Molecular Neurobiology, IBMC - Institute for Molecular and Cell Biology Porto , Porto , Portugal., Fishman S; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Willoughby JL; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Borland TD; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Milstein S; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Foster DJ; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Gonçalves P; b Instituto de Investigação e Inovação em Saúde, Universidade do Porto , Porto , Portugal .; c Molecular Neurobiology, IBMC - Institute for Molecular and Cell Biology Porto , Porto , Portugal., Chen Q; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Qin J; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Bettencourt BR; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Sah DW; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Alvarez R; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Rajeev KG; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Manoharan M; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Fitzgerald K; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Meyers RE; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Nochur SV; a Alnylam Pharmaceuticals , Cambridge , MA , USA ., Saraiva MJ; b Instituto de Investigação e Inovação em Saúde, Universidade do Porto , Porto , Portugal .; c Molecular Neurobiology, IBMC - Institute for Molecular and Cell Biology Porto , Porto , Portugal., Zimmermann TS; a Alnylam Pharmaceuticals , Cambridge , MA , USA .
Publikováno v:
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis [Amyloid] 2016 Jun; Vol. 23 (2), pp. 109-18. Date of Electronic Publication: 2016 Mar 31.
Autor:
Gottlieb J; Department of Respiratory Medicine, Hannover Medical School, Biomedical Research in End stage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Germany. Electronic address: gottlieb.jens@mh-hannover.de., Zamora MR; Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado at Denver Health Sciences Center, Aurora, Colorado., Hodges T; Center for Thoracic Transplantation at the Heart & Lung Institute, St. Joseph's Hospital and Medical Center, Phoenix, AZ., Musk AW; Department of Respiratory Medicine, Royal Perth Hospital, Perth, Australia., Sommerwerk U; Department of Pneumology, Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitaetsklinikum Essen GmbH, Essen, Germany., Dilling D; Departemnt of Medicine, Loyola University Medical Center, Maywood, IL, USA., Arcasoy S; Department of Medicine, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY., DeVincenzo J; Department of Pediatrics, University of Tennessee Center for Health Sciences, Memphis, Tennessee., Karsten V; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Shah S; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Bettencourt BR; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Cehelsky J; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Nochur S; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Gollob J; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Vaishnaw A; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Simon AR; Alnylam Pharmaceuticals, Cambridge, Massachusetts., Glanville AR; Lung Transplant Unit, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia.
Publikováno v:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [J Heart Lung Transplant] 2016 Feb; Vol. 35 (2), pp. 213-21. Date of Electronic Publication: 2015 Sep 03.
Autor:
Suhr OB; Department of Public Health and Clinical Medicine, Umeå University, 901 87, Umeå, Sweden. Ole.suhr@medicin.umu.se., Coelho T; Hospital de Santo António, Centro Hospitalar do Porto, 4099-001, Porto, Portugal. tcoelho@netcabo.pt., Buades J; Servicio de Medicina Interna, Hospital Son Llatzer, Carretera Manacor KM, 7198, Palma de Mallorca, Spain. doctorjuanbuades@gmail.com., Pouget J; Hôpital de La Timone, 264 rue Saint Pierre, 13005, Marseille, France. jeanyves.pouget@ap-hm.fr., Conceicao I; Centro Hospitalar Lisboa Norte-Hospital de Santa Maria, Piso 7, Av, Prof Eqas Moniz, Lisboa, 1649-028, Portugal. imsconceicao@gmail.com., Berk J; Boston University, 72 East Concord Street, K-503, Boston, MA, 02118, USA. jberk@bu.edu., Schmidt H; Universitätsklinikum Münster, Transplant Hepatology, Domagkstr. 3A, Munster, 48149, Germany. hepar@ukmuenster.de., Waddington-Cruz M; Hospital Universitário Clementino Fraga Filho, Federal University of Rio de Janeiro, Ilha do Fundao, Rio de Janeiro, CEP21941-913, Brazil. mwaddingtoncruz@gmail.com., Campistol JM; Hospital Clinic, University of Barcelona, IDIBAPS, Escalera 12 (5 Planta), C/ Villarroel, 170, Barcelona, 8036, Spain. jmcampis@clinic.ub.es., Bettencourt BR; Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA, 02142, USA. bbettencourt@alnylam.com., Vaishnaw A; Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA, 02142, USA. avaishnaw@alnylam.com., Gollob J; Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA, 02142, USA. jgollob@alnylam.com., Adams D; National Reference Center for FAP (NNERF)/ APHP/ INSERM U 1191/ Hôpital de Bicêtre, 78, rue du General Leclerc, 94275, Le Kremlin-Bicêtre, France. david.adams@bct.aphp.fr.
Publikováno v:
Orphanet journal of rare diseases [Orphanet J Rare Dis] 2015 Sep 04; Vol. 10, pp. 109. Date of Electronic Publication: 2015 Sep 04.
Autor:
Adams D; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA. david.adams@bct.aphp.fr., Coelho T; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Obici L; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Merlini G; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Mincheva Z; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Suanprasert N; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Bettencourt BR; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Gollob JA; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Gandhi PJ; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Litchy WJ; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA., Dyck PJ; From the National Reference Center for FAP (NNERF) (D.A., Z.M.), APHP, Univ Paris Sud, INSERM Unité 1195, Le Kremlin-Bicêtre, France; Hospital de Santo António (T.C.), Centro Hospitalar do Porto, Portugal; Amyloidosis Research and Treatment Center (L.O., G.M.), Foundation IRCCS Policlinico San Matteo and University of Pavia, Italy; Mayo Clinic (N.S., W.J.L., P.J.D.), Rochester, MN; and Alnylam Pharmaceuticals (B.R.B., J.A.G., P.J.G.), Cambridge, MA.
Publikováno v:
Neurology [Neurology] 2015 Aug 25; Vol. 85 (8), pp. 675-82. Date of Electronic Publication: 2015 Jul 24.
Autor:
Suanprasert N; Peripheral Neuropathy Research Laboratory, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA., Berk JL; Amyloidosis Center, Department of Neurology, Boston University School of Medicine, 72 East Concord Street, K504, Boston, MA 02118, USA., Benson MD; Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, 635 Barnhill Drive, Indianapolis, IN 46202, USA., Dyck PJ; Peripheral Neuropathy Research Laboratory, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA., Klein CJ; Peripheral Neuropathy Research Laboratory, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA., Gollob JA; Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA., Bettencourt BR; Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA., Karsten V; Alnylam Pharmaceuticals, 300 Third Street, Cambridge, MA 02142, USA., Dyck PJ; Peripheral Neuropathy Research Laboratory, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address: dyck.peter@mayo.edu.
Publikováno v:
Journal of the neurological sciences [J Neurol Sci] 2014 Sep 15; Vol. 344 (1-2), pp. 121-8. Date of Electronic Publication: 2014 Jun 27.